Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRR1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,868
Award facts
- Contract value 100% obligated
- $18,868.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,868.32 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Trikafta 100-50-75 mg/150 mg tablets (84-count supply). The award, issued on December 22, 2025, with an ultimate completion date of December 23, 2025, utilizes firm fixed-price pricing and includes no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy established to provide pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has served as a critical pharmaceutical supplier to the federal military medical system since its establishment as a prime vendor contractor under the PPV-G GEN V program on November 13, 2025. The company's contract encompasses a 30-month base period with three 30-month option periods through December 31, 2036, authorizing the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, and medical consumables. This delivery order for Trikafta, a cystic fibrosis treatment, represents routine pharmaceutical supply fulfillment consistent with DMS Pharmaceutical Group's demonstrated performance across diverse therapeutic categories and product lines supporting Department of Defense military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCRR1?
SPE2DR26FCRR1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 22, 2025.
How much is contract SPE2DR26FCRR1 worth?
The government has obligated $18,868 on SPE2DR26FCRR1.
Is contract SPE2DR26FCRR1 an order under another contract?
Yes. SPE2DR26FCRR1 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRR1 competed?
The extent of competition for SPE2DR26FCRR1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award